Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.58 |
| ▸ | TK1 | P04183 | 2/20 | 0.54 |
| ▸ | TK2 | O00142 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18007481 | 0.91 | TYMP (0.54) | TYMPTK1TK2 | |
| SCHEMBL1904388 | 0.88 | TYMP (0.59) | TYMPTK1TK2 | |
| SCHEMBL15329291 | 0.87 | TYMP (0.58) | TYMPTK1TK2 | |
| SCHEMBL19813715 | 0.85 | TK2 (0.56) | TYMPTK2 | |
| SCHEMBL15329018 | 0.85 | TYMP (0.55) | TYMPTK1TK2 | |
| SCHEMBL19813720 | 0.84 | TYMP (0.57) | TYMPTK2 | |
| SCHEMBL19813717 | 0.84 | TYMP (0.57) | TYMPTK2 | |
| SCHEMBL20360642 | 0.84 | TYMP (0.54) | TYMPTK1TK2 | |
| Clevudine SCHEMBL17847429 | 0.84 | TYMP (0.61) | TYMPTK2 | |
| 5-Methyl-2'-Fluoroarauracil SCHEMBL31010883 | 0.84 | TYMP (0.61) | TYMPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2025-04-17 | — | — | US | disclosed |
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3693463-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3052628-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2019-05-16 | — | — | US | disclosed |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| WO-2017048843-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
| EP-3052628-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015051318-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | TYMP 1373/4885TK1 1607/4885TK2 1484/4885 |
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | TYMP 1373/4885TK1 1607/4885TK2 1484/4885 |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | TYMP 1373/4885TK1 1607/4885TK2 1484/4885 |
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | TYMP 1373/4885TK1 1607/4885TK2 1484/4885 |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | TYMP 1373/4885TK1 1607/4885TK2 1484/4885 |
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | TYMP 1373/4885TK1 1607/4885TK2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.